Help
RSS
API
Feed
Maltego
Contact
Domain > apellis.eu
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2026-01-23
3.75.108.146
(
ClassC
)
Port 80
HTTP/1.1 200 OKDate: Thu, 09 Jan 2025 19:26:05 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveVary: Accept-EncodingServer: Pagely-ARES/1.21.14X-Gateway-Request !doctype html>html langen> head> meta charsetUTF-8> meta nameviewport contentwidthdevice-width, initial-scale1.0> meta namerobots contentindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1 /> style>img:is(sizesauto i, sizes^auto, i) { contain-intrinsic-size: 3000px 1500px }/style> link relalternate hrefhttp://apellis.eu/ hreflangen />link relalternate hrefhttp://apellis.eu/de/ hreflangde /> !-- This site is optimized with the Yoast SEO plugin v24.2 - https://yoast.com/wordpress/plugins/seo/ --> title>Official Home Page of the Apellis Pharmaceuticals Corporate Site | Apellis Pharmaceuticals/title> meta namedescription contentApellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. /> link relcanonical hrefhttp://apellis.eu/ /> meta propertyog:locale contenten_US /> meta propertyog:locale:alternate contentde_DE /> meta propertyog:type contentwebsite /> meta propertyog:title contentOfficial Home Page of the Apellis Pharmaceuticals Corporate Site | Apellis Pharmaceuticals /> meta propertyog:description contentApellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. /> meta propertyog:url contenthttp://apellis.eu/ /> meta propertyog:site_name contentApellis EU /> meta propertyarticle:modified_time content2024-08-30T09:24:17+00:00 /> meta nametwitter:card contentsummary_large_image /> script typeapplication/ld+json classyoast-schema-graph>{@context:https://schema.org,@graph:{@type:WebPage,@id:http://apellis.eu/,url:http://apellis.eu/,name:Official Home Page of the Apellis Pharmaceuticals Corporate Site | Apellis Pharmaceuticals,isPartOf:{@id:http://ape
Port 443
HTTP/1.1 200 OKDate: Thu, 09 Jan 2025 19:26:06 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveVary: Accept-EncodingServer: Pagely-ARES/1.21.14X-Gateway-Request !doctype html>html langen> head> meta charsetUTF-8> meta nameviewport contentwidthdevice-width, initial-scale1.0> meta namerobots contentindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1 /> style>img:is(sizesauto i, sizes^auto, i) { contain-intrinsic-size: 3000px 1500px }/style> link relalternate hrefhttp://apellis.eu/ hreflangen />link relalternate hrefhttp://apellis.eu/de/ hreflangde /> !-- This site is optimized with the Yoast SEO plugin v24.2 - https://yoast.com/wordpress/plugins/seo/ --> title>Official Home Page of the Apellis Pharmaceuticals Corporate Site | Apellis Pharmaceuticals/title> meta namedescription contentApellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. /> link relcanonical hrefhttp://apellis.eu/ /> meta propertyog:locale contenten_US /> meta propertyog:locale:alternate contentde_DE /> meta propertyog:type contentwebsite /> meta propertyog:title contentOfficial Home Page of the Apellis Pharmaceuticals Corporate Site | Apellis Pharmaceuticals /> meta propertyog:description contentApellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. /> meta propertyog:url contenthttp://apellis.eu/ /> meta propertyog:site_name contentApellis EU /> meta propertyarticle:modified_time content2024-08-30T09:24:17+00:00 /> meta nametwitter:card contentsummary_large_image /> script typeapplication/ld+json classyoast-schema-graph>{@context:https://schema.org,@graph:{@type:WebPage,@id:http://apellis.eu/,url:http://apellis.eu/,name:Official Home Page of the Apellis Pharmaceuticals Corporate Site | Apellis Pharmaceuticals,isPartOf:{@id:http://ape
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]